China’s NMPA authorises Santen’s glaucoma treatment application
China’s National Medical Products Administration (NMPA) has approved the marketing authorisation application of Santen Pharmaceutical's Tapcom to treat individuals with …
-
-
Obesity drugs won’t be covered by Medicare under 2026 CMS policy
The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal …
-
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC) …
-
ABL Bio and GSK link on neurodegenerative conditions
ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative conditions. Through this …
-
Uveitis market expected to reach $1.5bn across 7MM by 2033
The uveitis market is expected to grow at a compound annual growth rate of 10.9% throughout the forecast period (2023 …
-
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to …
-
‘Fear and uncertainty’ linger over FDA’s future in wake of Trump admin’s layoffs
This week, the Trump administration followed through on its plans for mass layoffs at health agencies under the US Department …
-
Streeting promises UK pharma quick action on VPAG frustration
The UK pharma industry can expect resolutions on a range of issues, including VPAG [Voluntary Scheme for Branded Medicines Pricing …
-
NBE Therapeutics opens ADC research facility in Switzerland
Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) research and development (R&D) facility in Basel, Switzerland. The …
-
Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research
Dementia affects millions of people worldwide, causing a serious impact on the economy and the healthcare system. Alzheimer’s disease (AD) …
-
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration (FDA) orphan drug designation …
-
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for …
-
IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility
Chimeric antigen receptor (CAR) T cell therapies have made remarkable strides in treating high-risk B-cell malignancies since the first CAR-T, …
-
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs) …
-
ABPI calls on UK Government to resolve “VPAG crisis”
Leaders of the Association of the British Pharmaceutical Industry (ABPI) say the UK Government must address rising clawback rates on …
